TACE + adebrelimab + bevacizumab

This is a combination therapy consisting of transarterial chemoembolization (TACE), adebrelimab, and bevacizumab. TACE is a minimally invasive procedure used primarily to treat liver cancer by delivering chemotherapy directly into the blood vessels feeding a tumor and then blocking those vessels with embolic agents, thereby trapping the drug in the tumor and cutting off its blood supply[1][2][3][4]. Adebrelimab is an anti-PD-L1 monoclonal antibody immunotherapy (not detailed in search results but known from current literature). Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thus reducing tumor vascularization[6][8]. This combination aims to maximize local cytotoxicity (via TACE), enhance immune-mediated antitumor activity (adebrelimab), and inhibit new blood vessel formation required for tumor growth (bevacizumab)[5].

Other names

transarterial chemoembolizationAVASTIN